GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIK · Mar 31, 2024

Anika Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001171843-24-002682General Corporate
Capex intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

4.46% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-0.31% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

6.85% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

121.93% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

60.78% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.operating_margin

-12.49% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

20.15% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

8.86% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
3.26%
Current
4.46%
Delta
1.21%
Cash Generation Increased
Previous
-1.07%
Current
-0.31%
Delta
0.76%
Growth Increased
Previous
6.67%
Current
6.85%
Delta
0.18%
Inventory Pressure Increased
Previous
27.83%
Current
121.93%
Delta
94.09%
Margin Decreased
Previous
61.85%
Current
60.78%
Delta
-1.08%
Profitability Increased
Previous
-52.58%
Current
-12.49%
Delta
40.09%
R And D Intensity Increased
Previous
19.61%
Current
20.15%
Delta
0.53%
Sbc Intensity Decreased
Previous
9.15%
Current
8.86%
Delta
-0.29%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIK Fundamental State →Has State · Anika Therapeutics, Inc. →Transitioned To · ANIK Fundamental State →Transitioned To · ANIK CAPEX_INTENSITY_INCREASED →Transitioned To · ANIK CASH_GENERATION_INCREASED →Transitioned To · ANIK GROWTH_INCREASED →Transitioned To · ANIK INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIK MARGIN_DECREASED →Transitioned To · ANIK PROFITABILITY_INCREASED →Transitioned To · ANIK R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIK SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.